#BEGIN_DRUGCARD DB00507

# AHFS_Codes:
Not Available

# ATC_Codes:
P01AX11

# Absorption:
The relative bioavailability of the suspension compared to the tablet was 70%. When administered with food the AUC and C<sub>max</sub> increased by two-fold and 50%, respectively, for the tablet and 45 to 50% and &le; 10%, respectively, for the oral suspension.

# Biotransformation:
Rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide), followed by conjugation, primarily by glucuronidation to tizoxanide glucuronide.

# Brand_Mixtures:
Not Available

# Brand_Names:
Alinia
Phavic-1

# CAS_Registry_Number:
55981-09-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C12H9N3O5S

# Chemical_IUPAC_Name:
2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Nitazoxanide, also known by the brand name Alinia, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1–4 hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea. [Wikipedia]

# Dosage_Forms:
Suspension	Oral
Tablet	Oral

# Drug_Category:
Antiparasitic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
15504227	Parasitic infections. Am J Transplant. 2004 Nov;4 Suppl 10:142-55.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.2

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nitazoxanide

# HET_ID:
Not Available

# Half_Life:
3.5 hours in patients with normal renal function

# InChI_Identifier:
InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)

# InChI_Key:
InChIKey=YQNQNVDNTFHQSW-UHFFFAOYSA-N

# Indication:
For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i> and for the treatment of diarrhea in children caused by the protozoa <i>Cryptosporidium parvum</i>.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02486

# LIMS_Drug_ID:
507

# Mechanism_Of_Action:
The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from Giardia lamblia directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of Cryptosporidium parvum appears to be similar to that of Giardia lamblia. Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity.

# Melting_Point:
202 °C

# Molecular_Weight_Avg:
307.282

# Molecular_Weight_Mono:
307.026291103

# Organisms_Affected:
Protozoa

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ali1659.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164754874

# Pharmacology:
Nitazoxanide is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that nitazoxanide inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Nitazoxanide is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, nitazoxanide is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

# Predicted_LogP_Hydrophobicity:
2.14

# Predicted_LogS:
-4.6

# Predicted_Water_Solubility:
7.55e-03 g/l

# Primary_Accession_No:
DB00507

# Protein_Binding:
Very High (greater than 99%), bound to proteins. Binding is not affected by degree of renal impairment.

# PubChem_Compound_ID:
41684

# PubChem_Substance_ID:
46507813

# RxList_Link:
http://www.rxlist.com/cgi/generic/alinia.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00558

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide
2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide
Nitazoxanid
Nitazoxanida [INN-Spanish]
Nitazoxanidum [INN-Latin]
Tizoxanide Glucuronide

# Synthesis_Reference:
Not Available

# Toxicity:
In acute studies in rodents and dogs, the oral LD<sub>50</sub> was higher than 10,000 mg/kg. Single oral doses of up to 4000 mg nitazoxanide have been administered to healthy adult volunteers without significant adverse effects.

# Update_Date:
2013-02-08 16:19:24 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nitazoxanide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17158936	Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG: Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007 Mar;51(3):868-76. Epub 2006 Dec 11.
20488706	Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Hoffman PS, Macdonald TL: Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3537-9. Epub 2010 May 18.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Y09702

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
por

# Drug_Target_1_Gene_Sequence:
>3699 bp
ATGGGAAAGAAAATGATGACGACTGATGGCAATACAGCGACAGCGCACGTGGCGTATGCC
ATGAGCGAAGTCGCCGCCATCTACCCCATCACCCCTTCCTCGACCATGGGCGAGGAGGCT
GACGACTGGGCGGCGCAAGGACGCAAGAACATCTTTGGCCAGACCCTGACCATACGCGAA
ATGCAGTCCGAGGCCGGCGCCGCCGGCGCGGTGCACGGGGCCCTGGCGGCCGGCGCCCTG
ACCACGACCTTCACGGCGTCGCAGGGTCTGCTGCTGATGATCCCCAACATGTACAAGATC
TCCGGCGAACTTCTGCCCGGCGTGTTCCACGTCACCGCCCGCGCCATCGCCGCGCACGCC
CTGTCCATCTTCGGTGACCACCAGGATATCTACGCCGCGCGCCAGACAGGCTTCGCCATG
CTCGCCTCCAGCTCGGTGCAGGAGGCCCACGACATGGCCCTGGTGGCCCACTTGGCGGCC
ATCGAGTCCAACGTGCCGTTCATGCACTTCTTCGACGGATTCCGCACCTCGCACGAAATC
CAGAAGATCGAGGTCCTGGACTACGCGGACATGGCCTCGCTGGTGAACCAGAAGGCCCTG
GCGGAATTCCGCGCCAAGTCCATGAACCCCGAGCACCCCCACGTGCGCGGCACGGCCCAG
AACCCCGACATCTACTTCCAGGGTCGCGAGGCAGCCAACCCCTACTACCTCAAGGTGCCC
GGCATCGTTGCCGAGTACATGCAGAAGGTCGCCTCCCTCACGGGCCGCAGCTACAAGCTC
TTTGACTACGTGGGTGCTCCCGACGCCGAGCGCGTCATCGTGTCCATGGGCTCCTCGTGC
GAGACCATCGAGGAGGTCATCAACCACCTCGCGGCCAAGGGCGAAAAGATCGGCCTGATC
AAGGTCCGCCTGTACAGGCCCTTCGTAAGCGAGGCCTTCTTCGCTGCTCTGCCCGCTTCG
GCCAAGGTCATCACGGTCCTCGACCGCACCAAGGAACCCGGCGCGCCCGGCGATCCGCTC
TACCTCGACGTGTGCTCGGCCTTCGTGGAGCGCGGCGAAGCCATGCCCAAGATCCTGGCC
GGCCGCTACGGCCTGGGTTCCAAGGAATTCAGCCCGGCCATGGTCAAGTCCGTGTACGAC
AACATGTCCGGCGCTAAGAAGAACCACTTCACCGTGGGCATCGAAGACGACGTGACCGGC
ACTTCGCTGCCGGTGGACAACGCCTTCGCCGACACCACGCCCAAGGGCACCATCCAGTGC
CAGTTCTGGGGCCTCGGCGCCGACGGCACTGTGGGCGCCAACAAGCAGGCCATCAAGATC
ATCGGCGACAACACGGACCTGTTTGCCCAGGGTTACTTCTCCTACGACTCCAAGAAATCG
GGCGGCATCACCATCTCGCACCTGCGCTTCGGCGAGAAGCCCATCCAGTCCACCTACCTG
GTCAACAGGGCCGACTATGTCGCCTGTCACAACCCGGCCTACGTGGGCATATACGACATC
CTCGAAGGCATCAAGGATGGCGGAACCTTCGTGCTCAACTCGCCTTGGAGCAGCCTCGAG
GACATGGACAAGCACCTGCCCTCCGGCATCAAGCGCACCATCGCGAACAAGAAGCTCAAG
TTCTACAACATCGACGCGGTGAAAATCGCCACCGATGTGGGACTGGGCGGCCGCATCAAC
ATGATCATGCAGACGGCCTTCTTCAAGCTGGCCGGAGTGCTGCCCTTCGAAAAGGCCGTG
GATCTGCTCAAGAAGTCCATCCACAAGGCCTACGGCAAAAAGGGCGAGAAGATCGTCAAG
ATGAACACCGACGCCGTGGACCAGGCCGTCACCTCCCTGCAGGAATTCAAGTATCCGGAT
TCCTGGAAGGACGCTCCCGCTGAGACCAAGGCCGAGCCCATGACGAACGAGTTCTTCAAG
AACGTCGTCAAGCCCATCCTGACCCAGCAGGGCGACAAGCTGCCGGTGAGCGCCTTCGAG
GCCGACGGCCGTTTCCCCCTCGGCACCAGCCAGTTCGAGAAGCGCGGCGTGGCCATCAAC
GTGCCGCAGTGGGTCCCCGAGAACTGCATCCAGTGCAACCAGTGCGCCTTCGTCTGTCCG
CACAGCGCCATCCTGCCCGTGCTGGCCAAGGAAGAGGAGTTGGTCGGCGCGCCGGCGAAC
TTCACGGCCCTGGAAGCCAAGGGCAAGGAGCTCAAGGGCTACAAGTTCCGCATCCAGATC
AACACCCTGGACTGCATGGGCTGCGGCAACTGCGCCGACATCTGTCCGCCCAAGGAAAAG
GCTCTGGTCATGCAGCCCCTGGATACCCAGCGCGACGCGCAGGTGCCCAACCTGGAGTAC
GCAGCGCGCATCCCGGTCAAATCCGAGGTGCTGCCGCGCGACTCGCTCAAGGGCAGCCAG
TTCCAGGAGCCTCTCATGGAATTCTCGGGCGCCTGCTCGGGCTGCGGCGAGACGCCCTAC
GTGCGCGTCATCACCCAGCTCTTCGGCGAGCGCATGTTCATTGCCAACGCCACGGGTTGC
TCGTCCATCTGGGGCGCGTCGGCTCCTTCCATGCCTTACAAGACCAACCGCCTCGGACAA
GGCCCGGCCTGGGGTAACTCCCTGTTCGAAGACGCGGCCGAATACGGCTTCGGCATGAAC
ATGTCCATGTTCGCCCGCCGCACGCATTTGGCCGATCTTGCCGCCAAGGCCCTGGAGAGC
GATGCCTCCGGCGATGTCAAGGAAGCCCTGCAGGGCTGGCTTGCCGGCAAGAACGATCCC
ATCAAGTCCAAGGAATACGGCGACAAGCTCAAGAAGCTGCTGGCTGGTCAGAAGGATGGT
CTGCTCGGACAGATCGCCGCCATGTCCGACCTGTACACCAAGAAGAGCGTGTGGATCTTC
GGTGGCGACGGCTGGGCCTACGACATCGGTTACGGCGGCCTGGACCATGTGCTCGCCTCG
GGCGAGGACGTGAACGTCTTCGTCATGGATACCGAGGTCTACTCCAACACCGGCGGCCAG
TCCTCCAAGGCAACGCCCACGGGCGCCGTGGCCAAGTTCGCGGCGGCCGGCAAGCGTACC
GGCAAGAAGGACCTGGCGCGCATGGTCATGACCTACGGCTACGTCTACGTGGCTACGGTC
TCCATGGGTTACAGCAAGCAGCAGTTCCTCAAGGTGCTCAAGGAAGCCGAAAGCTTCCCC
GGCCCCTCGCTGGTCATCGCCTATGCTACCTGCATCAACCAGGGTCTGCGCAAGGGCATG
GGCAAGAGCCAGGACGTCATGAACACCGCGGTCAAGTCCGGTTACTGGCCGCTGTTCCGC
TACGATCCGCGCTTGGCCGCCCAGGGCAAGAACCCCTTCCAGCTCGACTCCAAGGCTCCT
GACGGTTCCGTCGAGGAGTTCCTGATGGCCCAGAACCGCTTCGCCGTCCTCGATCGGTCC
TTCCCCGAGGACGCCAAGAGACTGCGCGCCCAGGTCGCTCACGAATTGGACGTGCGTTTC
AAGGAGTTGGAGCACATGGCCGCCACGAACATCTTCGAGTCCTTCGCGCCAGCGGGCGGC
AAGGCCGATGGTTCGGTGGATTTCGGCGAAGGTGCGGAGTTCTGCACGCGCGACGATACT
CCCATGATGGCCCGACCTGATTCCGGTGAGGCCTGCGACCAGAACCGCGCTGGCACGAGC
GAACAGCAGGGAGACCTCAGCAAGCGGACGAAGAAGTAG

# Drug_Target_1_General_Function:
Involved in electron carrier activity

# Drug_Target_1_General_References:
10048931	Chabriere E, Charon MH, Volbeda A, Pieulle L, Hatchikian EC, Fontecilla-Camps JC: Crystal structures of the key anaerobic enzyme pyruvate:ferredoxin oxidoreductase, free and in complex with pyruvate. Nat Struct Biol. 1999 Feb;6(2):182-90.
11752578	Chabriere E, Vernede X, Guigliarelli B, Charon MH, Hatchikian EC, Fontecilla-Camps JC: Crystal structure of the free radical intermediate of pyruvate:ferredoxin oxidoreductase. Science. 2001 Dec 21;294(5551):2559-63.
9294422	Pieulle L, Magro V, Hatchikian EC: Isolation and analysis of the gene encoding the pyruvate-ferredoxin oxidoreductase of Desulfovibrio africanus, production of the recombinant enzyme in Escherichia coli, and effect of carboxy-terminal deletions on its stability. J Bacteriol. 1997 Sep;179(18):5684-92.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4562

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
133682

# Drug_Target_1_Name:
Pyruvate-ferredoxin oxidoreductase

# Drug_Target_1_Number_of_Residues:
1232

# Drug_Target_1_PDB_ID:
2PDA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00037	Fer4
PF01558	POR
PF01855	POR_N
PF02775	TPP_enzyme_C

# Drug_Target_1_Protein_Sequence:
>Pyruvate-ferredoxin oxidoreductase
MGKKMMTTDGNTATAHVAYAMSEVAAIYPITPSSTMGEEADDWAAQGRKNIFGQTLTIRE
MQSEAGAAGAVHGALAAGALTTTFTASQGLLLMIPNMYKISGELLPGVFHVTARAIAAHA
LSIFGDHQDIYAARQTGFAMLASSSVQEAHDMALVAHLAAIESNVPFMHFFDGFRTSHEI
QKIEVLDYADMASLVNQKALAEFRAKSMNPEHPHVRGTAQNPDIYFQGREAANPYYLKVP
GIVAEYMQKVASLTGRSYKLFDYVGAPDAERVIVSMGSSCETIEEVINHLAAKGEKIGLI
KVRLYRPFVSEAFFAALPASAKVITVLDRTKEPGAPGDPLYLDVCSAFVERGEAMPKILA
GRYGLGSKEFSPAMVKSVYDNMSGAKKNHFTVGIEDDVTGTSLPVDNAFADTTPKGTIQC
QFWGLGADGTVGANKQAIKIIGDNTDLFAQGYFSYDSKKSGGITISHLRFGEKPIQSTYL
VNRADYVACHNPAYVGIYDILEGIKDGGTFVLNSPWSSLEDMDKHLPSGIKRTIANKKLK
FYNIDAVKIATDVGLGGRINMIMQTAFFKLAGVLPFEKAVDLLKKSIHKAYGKKGEKIVK
MNTDAVDQAVTSLQEFKYPDSWKDAPAETKAEPMTNEFFKNVVKPILTQQGDKLPVSAFE
ADGRFPLGTSQFEKRGVAINVPQWVPENCIQCNQCAFVCPHSAILPVLAKEEELVGAPAN
FTALEAKGKELKGYKFRIQINTLDCMGCGNCADICPPKEKALVMQPLDTQRDAQVPNLEY
AARIPVKSEVLPRDSLKGSQFQEPLMEFSGACSGCGETPYVRVITQLFGERMFIANATGC
SSIWGASAPSMPYKTNRLGQGPAWGNSLFEDAAEYGFGMNMSMFARRTHLADLAAKALES
DASGDVKEALQGWLAGKNDPIKSKEYGDKLKKLLAGQKDGLLGQIAAMSDLYTKKSVWIF
GGDGWAYDIGYGGLDHVLASGEDVNVFVMDTEVYSNTGGQSSKATPTGAVAKFAAAGKRT
GKKDLARMVMTYGYVYVATVSMGYSKQQFLKVLKEAESFPGPSLVIAYATCINQGLRKGM
GKSQDVMNTAVKSGYWPLFRYDPRLAAQGKNPFQLDSKAPDGSVEEFLMAQNRFAVLDRS
FPEDAKRLRAQVAHELDVRFKELEHMAATNIFESFAPAGGKADGSVDFGEGAEFCTRDDT
PMMARPDSGEACDQNRAGTSEQQGDLSKRTKK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Oxidoreductase required for the transfer of electrons from pyruvate to flavodoxin, which reduces nitrogenase (By similarity)

# Drug_Target_1_SwissProt_ID:
P94692

# Drug_Target_1_SwissProt_Name:
P94692_DESAF

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
6.81

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00507
